Spyre Therapeutics, Inc. (SYRE)
80.11
-12.61
(-13.60%)
USD |
NASDAQ |
Oct 06, 16:00
79.36
-0.75
(-0.94%)
Pre-Market: 08:22
Spyre Therapeutics EPS Diluted (Quarterly) : -0.4272 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.4272 |
| March 31, 2026 | -0.8785 |
| December 31, 2025 | -0.6903 |
| September 30, 2025 | -0.184 |
| June 30, 2025 | -0.6049 |
| March 31, 2025 | -0.5988 |
| December 31, 2024 | -0.7903 |
| September 30, 2024 | -1.056 |
| June 30, 2024 | -0.5904 |
| March 31, 2024 | -0.7232 |
| December 31, 2023 | 11.58 |
| September 30, 2023 | -9.341 |
| June 30, 2023 | -56.79 |
| March 31, 2023 | -4.886 |
| December 31, 2022 | -7.200 |
| September 30, 2022 | -4.839 |
| June 30, 2022 | -6.788 |
| March 31, 2022 | -9.256 |
| December 31, 2021 | -10.36 |
| September 30, 2021 | -7.717 |
| June 30, 2021 | -2.602 |
| March 31, 2021 | -6.942 |
| December 31, 2020 | -11.84 |
| September 30, 2020 | -7.243 |
| Date | Value |
|---|---|
| June 30, 2020 | -10.11 |
| March 31, 2020 | -14.15 |
| December 31, 2019 | -18.48 |
| September 30, 2019 | -16.40 |
| June 30, 2019 | -13.72 |
| March 31, 2019 | -14.79 |
| December 31, 2018 | -15.50 |
| September 30, 2018 | -13.55 |
| June 30, 2018 | -11.43 |
| March 31, 2018 | -12.17 |
| December 31, 2017 | -9.75 |
| September 30, 2017 | -12.00 |
| June 30, 2017 | -11.75 |
| March 31, 2017 | -11.75 |
| December 31, 2016 | -10.25 |
| September 30, 2016 | -11.75 |
| June 30, 2016 | -11.50 |
| March 31, 2016 | -177.50 |
| December 31, 2015 | -7.286 |
| September 30, 2015 | -6.237 |
| June 30, 2015 | -2.608 |
| March 31, 2015 | -4.927 |
| December 31, 2014 | -5.813 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AbbVie, Inc. | 2.033 |
| Incyte Corp. | 2.812 |
| SELLAS Life Sciences Group, Inc. | -0.0508 |
| Relay Therapeutics, Inc. | -0.4127 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -36.20M |
| Total Expenses (Quarterly) | 36.20M |
| Enterprise Value | 6.056B |
| Earnings Yield | -2.72% |
| Normalized Earnings Yield | -2.811 |